Anavex Life Sciences Corp.
AVXLNASDAQHealthcare● Active
$2.57
$-0.25(-8.87%)
Market Cap$238166418
P/E Ratio—
52W High$13.99
52W Low$2.56
Anavex Life Sciences Corp. (AVXL) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AVXL · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Jun 9, 2026EPS Actual
-$0.07
Est. -$0.07 · +0.0%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Jun 9, 2026
After Market Close
✓ 3-Quarter EPS Beat Streak
AVXL reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.08 | — | — | — | — | — |
| — Q2 FY2026 | Jun 9, 2026 | -$0.07 | -$0.07 | +0.0% | — | — | — |
| ▲ Q1 FY2026 | Feb 9, 2026 | -$0.10 | -$0.06 | +40.0% | — | — | — |
| ▲ Q4 FY2025 | Nov 25, 2025 | -$0.13 | -$0.11 | +15.4% | — | — | — |
| ▼ Q3 FY2025 | Aug 12, 2025 | -$0.13 | -$0.16 | -23.1% | — | — | — |
| ▲ Q2 FY2025 | May 13, 2025 | -$0.16 | -$0.13 | +18.8% | — | — | — |
| ▲ Q1 FY2025 | Feb 12, 2025 | -$0.17 | -$0.14 | +17.6% | — | — | — |
| ▲ Q4 FY2024 | Dec 23, 2024 | -$0.17 | -$0.14 | +17.6% | — | — | — |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.08
EPS Surpr.
—
Revenue
—
Q2 FY2026
Jun 9, 2026
EPS Actual
-$0.07
EPS Est.
-$0.07
EPS Surpr.
+0.0%
Revenue
—
Q1 FY2026
Feb 9, 2026Beat
EPS Actual
-$0.06
EPS Est.
-$0.10
EPS Surpr.
+40.0%
Revenue
—
Q4 FY2025
Nov 25, 2025Beat
EPS Actual
-$0.11
EPS Est.
-$0.13
EPS Surpr.
+15.4%
Revenue
—
Q3 FY2025
Aug 12, 2025Miss
EPS Actual
-$0.16
EPS Est.
-$0.13
EPS Surpr.
-23.1%
Revenue
—
Q2 FY2025
May 13, 2025Beat
EPS Actual
-$0.13
EPS Est.
-$0.16
EPS Surpr.
+18.8%
Revenue
—
Q1 FY2025
Feb 12, 2025Beat
EPS Actual
-$0.14
EPS Est.
-$0.17
EPS Surpr.
+17.6%
Revenue
—
Q4 FY2024
Dec 23, 2024Beat
EPS Actual
-$0.14
EPS Est.
-$0.17
EPS Surpr.
+17.6%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2028 | $0.59 | $0.59 | $0.59 | 1 |
| Q2 FY2028 | $0.56 | $0.56 | $0.56 | 1 |
| Q1 FY2028 | $0.56 | $0.56 | $0.56 | 1 |
| Q4 FY2027 | $0.55 | $0.55 | $0.55 | 1 |
| Q3 FY2027 | $-0.15 | $-0.15 | $-0.15 | 1 |
| Q2 FY2027 | $-0.14 | $-0.14 | $-0.14 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Jun 9, 2026 | +0.0% | $2.61 | — | — |
| ▲ Q1 FY2026 | Feb 9, 2026 | +40.0% | $4.10 | $4.35 | +6.10% |
| ▲ Q4 FY2025 | Nov 25, 2025 | +15.4% | $3.08 | $3.46 | +12.34% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -23.1% | $11.35 | $10.78 | -5.02% |
| ▲ Q2 FY2025 | May 13, 2025 | +18.8% | $8.55 | $8.12 | -5.03% |
| ▲ Q1 FY2025 | Feb 12, 2025 | +17.6% | $8.29 | $8.70 | +4.95% |
| ▲ Q4 FY2024 | Dec 23, 2024 | +17.6% | $8.63 | $11.18 | +29.55% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +6.7% | $6.45 | $6.82 | +5.74% |
Q2 FY2026—
Report Date
Jun 9, 2026
EPS Beat/Miss
+0.0%
Price Before
$2.61
Price After
—
Q1 FY2026+6.10%
Report Date
Feb 9, 2026
EPS Beat/Miss
+40.0%
Price Before
$4.10
Price After
$4.35
Q4 FY2025+12.34%
Report Date
Nov 25, 2025
EPS Beat/Miss
+15.4%
Price Before
$3.08
Price After
$3.46
Q3 FY2025-5.02%
Report Date
Aug 12, 2025
EPS Beat/Miss
-23.1%
Price Before
$11.35
Price After
$10.78
Q2 FY2025-5.03%
Report Date
May 13, 2025
EPS Beat/Miss
+18.8%
Price Before
$8.55
Price After
$8.12
Q1 FY2025+4.95%
Report Date
Feb 12, 2025
EPS Beat/Miss
+17.6%
Price Before
$8.29
Price After
$8.70
Q4 FY2024+29.55%
Report Date
Dec 23, 2024
EPS Beat/Miss
+17.6%
Price Before
$8.63
Price After
$11.18
Q3 FY2024+5.74%
Report Date
Aug 6, 2024
EPS Beat/Miss
+6.7%
Price Before
$6.45
Price After
$6.82
Avg Beat Reaction+8.94%
Avg Miss Reaction-5.02%
Beat Rate7 / 8 quarters
Largest Move+29.55% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AVXL ends December
Anavex Life Sciences Corp. (AVXL) most recently reported earnings on June 9, 2026 for Q2 FY2026, posting EPS of $-0.07 (in line with the analyst consensus of $-0.07). AVXL has beaten EPS estimates for 3 consecutive quarters. The next AVXL earnings date is expected around September 1, 2026.
Each quarter, investors track AVXL earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AVXL revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AVXL's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AVXL earnings · 4 questionsAnavex Life Sciences Corp.'s next earnings report is expected around September 1, 2026. AVXL typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AVXL historically reports after market close (AMC).
AVXL earnings datewhen is AVXL earningsAVXL next earnings datewhen does AVXL report earningsAVXL earnings calendar
▸ Source: FMP · Anavex Life Sciences Corp. SEC filings · US GAAP · Anavex Life Sciences Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026